Binding Characteristics of Drugs to Synthetic Levodopa Melanin
Overview
Pharmacy
Authors
Affiliations
To define binding characteristics of drugs, levodopa melanin was prepared with the aid of mushroom tyrosinase. The binding of radiolabeled substances was studied with increasing concentrations of melanin in a fixed volume of potassium phosphate buffer (pH 7.4) at 37 degrees. The affinity and capacity of the drug binding were calculated according to Langmuir's adsorption isotherm. The affinity constant of various sympathomimetic amines such as (-)-amphetamine, (+)-amphetamine, (-)-ephedrine, (+/-)-octopamine, and (+)-norepinephrine ranged from 1.1 to 2.8 X 10(5) M-1. The binding capacity for the amines ranged from 1.4 to 3.2 X 10(-9) mole/mg. Although the capacity of (+/-)-cocaine for binding was similar to that of the amines, the affinity was slightly higher, 8.9 X 10(5) M-1. The binding of atropine to the synthetic melanin appeared to be a saturable process with the affinity and capacity values of 0.2 X 10(5) M-1 and 7.6 X 10(-9) mole/mg, respectively. Although the binding lacks stereoselectivity, the drugs vary in their capacity and affinity to bind with melanin. The observed differential pharmacological and toxicologic properties of drugs in the pigmented tissues may in part be related to their differential bi binding characteristics.
Rudrappa M, Nayaka S, Kumar R Appl Biochem Biotechnol. 2023; 195(7):4368-4386.
PMID: 36692647 DOI: 10.1007/s12010-023-04358-4.
Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics.
Vervaeke P, Borgos S, Sanders N, Combes F Adv Drug Deliv Rev. 2022; 184:114236.
PMID: 35351470 PMC: 8957368. DOI: 10.1016/j.addr.2022.114236.
Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies.
Schroeder R, Gerber J Toxicol Rep. 2017; 1:963-968.
PMID: 28962308 PMC: 5598414. DOI: 10.1016/j.toxrep.2014.10.019.
The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide.
Du W, Sun S, Xu Y, Li J, Zhao C, Lan B J Ocul Pharmacol Ther. 2013; 29(7):633-8.
PMID: 23597073 PMC: 3757532. DOI: 10.1089/jop.2012.0226.
Bechshoft T, Riget F, Sonne C, Letcher R, Muir D, Novak M Environ Int. 2012; 45:15-21.
PMID: 22572112 PMC: 3366040. DOI: 10.1016/j.envint.2012.04.005.